-

Bristol Myers Squibb to Take Part in the UBS Virtual Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020. Samit Hirawat, MD, EVP, Chief Medical Officer and Chris Boerner, EVP, Chief Commercialization Officer will answer questions at 11:40 a.m. ET.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Contacts

Media:
media@bms.com
908-447-6134

Investor Relations:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, nina.goworek@bms.com

Bristol Myers Squibb Company

NYSE:BMY

Release Summary
Bristol Myers Squibb to Take Part in the UBS Virtual Global Healthcare Conference
Release Versions
$Cashtags

Contacts

Media:
media@bms.com
908-447-6134

Investor Relations:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, nina.goworek@bms.com

More News From Bristol Myers Squibb Company

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Positive Phase 3 Data from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma...

U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

PRINCETON, N.J.--(BUSINESS WIRE)--U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis...

Bristol Myers Squibb Announces Dividend

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend...
Back to Newsroom